Commercialization of regenerative products: The academic/industry partnership

Tissue Engineering - Part B: Reviews

Volumn 20, Issue 4, 2014, Pages 243-245

  Bayon, Yves ^a   Ellison, Simon ^b   Vertès, Alain ^c,d   Ahmed, Arshad ^e   Coury, Art J ^f   Campion, Charlie ^g,h   Bertram, Timothy A ⁱ   Hellman, Kiki B ^j  

^a MEDTRONIC INC   (United States)

^b NHS BLOOD AND TRANSPLANT   (United Kingdom)

^c LONDON BUSINESS SCHOOL   (United Kingdom)

^d NxR Biotechnologies   (Switzerland)

^e Scientia Advisors   (United States)

^f Coury Consulting Services ^*  (United States)

^g UNIVERSITY OF LONDON   (United Kingdom)

^h Apatech Ltd   (United Kingdom)

ⁱ Tengion Inc   (United States)

^j Hellman Group LLC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

COMMERCIAL PHENOMENA; COMMUNICATION DISORDER; FUNDING; HUMAN; INVENTION; INVESTMENT; MARKET; PATENT; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; PUBLIC-PRIVATE PARTNERSHIP; REGENERATIVE MEDICINE; REVIEW; ORGANIZATION; TECHNOLOGY;

BIOMATERIAL;

ACADEMIES AND INSTITUTES; BIOCOMPATIBLE MATERIALS; HUMANS; REGENERATIVE MEDICINE; TECHNOLOGY TRANSFER;

EID: 84905578035     PISSN: 19373368     EISSN: 19373376     Source Type: Journal    
DOI: 10.1089/ten.teb.2012.0683     Document Type: Review

References (7)

1. Johnson, P.C., Bertram, T.A., Tawil, B., and Hellman, K.B. Hurdles in tissue engineering/regenerative medicine product commercialization: A survey of North American academia and industry. Tissue Eng, Part A 17, 5, 2011
2. Mason, C., and Manzotti, E. Regenerative medicine cell therapies: Numbers of units manufactured and patients treated between 1988 and 2010. Regen Med 5, 307, 2010
3. Villiger, R., and Bogdan, B. Dissecting monoclonal antibodies mega-deals. mABS 1, 172, 2009
4. Vertès, A.A. Time to engage with stem-cell therapeutics. Med Nous April 27th, 20, 2012
5. Anonymous. 2010-2011-2012. Trend analysis. http://onbiovc .com/
6. Vertès, A.A. Syndicate innovation venturing: Translating academic innovation into academic success. Challenges 3, 70, 2012
7. Waltz, E. Start-ups weigh benefits of corporate incubators. Nat Biotechnol 26, 254, 2008